Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055


Delayed Quote. Delayed Nyse - 04/20 04:03:01 pm
57.61 USD   +1.28%
11:07a DOW MOVERS : Ge, ibm
08:44aDJU.S. Stock Futures Advance
08:03a MERCK : TetraLogic and Merck to Collaborate on the Evaluation of Bir..
News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.


-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at

Subscribe to WSJ:

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
React to this article
Latest news on MERCK & CO., INC.
11:07a DOW MOVERS : Ge, ibm
08:44aDJU.S. Stock Futures Advance
08:03a MERCK : TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in C..
01:03aDJU.S. Stocks Advance
04/19DJMerck Drug Shows Improved Odds for Melanoma Patients--Update
04/19 MERCK : drug Keytruda effective against 3 cancers (Studies)
04/19 MERCK : Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 T..
04/19 MERCK : Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 The..
04/19DJMerck's Keytruda Shows Improved Survival Odds for Melanoma Patients
04/19 MERCK : Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® ..
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes